Clinical Trial Results: Cytomegalovirus infections

Product Name: Valcyte [valganciclovir]
Date of Report: 3/1/2004
Phase: III
An Open-Label Study of the Safety and Tolerability of Valganciclovir, an Oral Prodrug of Ganciclovir, for the Treatment of Cytomegalovirus Retinitis in Subjects with AIDS

Product Name: Valcyte [valganciclovir]
Date of Report: 3/1/2004
Phase: III
A Randomized Controlled Comparison of the Safety and Efficacy of Ro107-9070 (Valganciclovir) vs Intravenous Ganciclovir as Induction Therapy for the Treatment of Newly Diagnosed Cytomegalovirus Retinitis

Product Name: Valcyte [valganciclovir]
Date of Report: 3/4/2005
Phase: II
The pharmacokinetics of ganciclovir following a dose of valganciclovir vs iv ganciclovir in bone marrow transplant or human stem cell transplant (BMT/HSCT) patients with stable graft-versus-host disease (GVHD) who have gut involvement

Product Name: Valcyte [valganciclovir]
Date of Report: To be Published
Phase: II
A Study of PCR-Based Pre-Emptive Therapy With Valcyte (Valganciclovir) and Ganciclovir for Cytomegalovirus (CMV) Infection After Stem Cell Transplantation

Product Name: Valcyte [valganciclovir]
Date of Report: To be Published
Phase: II
A Study of Valcyte (Valganciclovir) Syrup Formulation in Pediatric Solid Organ Transplant Recipients

Product Name: Valcyte [valganciclovir]
Date of Report: To be Published
Phase: IV
VICTOR study A Study of Valcyte (Valganciclovir po) Compared With Ganciclovir iv in Patients With Cytomegalovirus (CMV) Disease Who Are Solid Organ Transplant Recipients

Product Name: Valcyte [valganciclovir]
Date of Report: To be Published
Phase: III
IMPACT study: A Study of Valcyte (Valganciclovir) for Prevention of Cytomegalovirus Disease (CMV) in Kidney Allograft Recipients

Product Name: Valcyte [valganciclovir]
Date of Report: To be Published
Phase: IV
A Study of Valcyte (Valganciclovir) CMV Prophylaxis after Renal Transplantation

Product Name: Valcyte [valganciclovir]
Date of Report: To be Published
Phase: I
A Relative Bioavailability Study of Valcyte (valganciclovir) in Lung Transplant Recipients With or Without Cystic Fibrosis.